These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32575357)

  • 1. The PK/PD Integration and Resistance of Tilmicosin against
    Huang Z; Hu Z; Zheng H; Xia X; Gu X; Shen X; Yang H; Ding H
    Pathogens; 2020 Jun; 9(6):. PubMed ID: 32575357
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Huang Z; Wu Y; Zhou Z; Xia X; Gu X; Cai Q; Shen X; Yang H; Ding H
    Front Pharmacol; 2019; 10():670. PubMed ID: 31293418
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic integration and resistance of tiamulin against Mycoplasma hyopneumoniae in an in vitro dynamic model.
    Huang Z; Xia X; Mao C; Gu X; Shen X; Yang H; Ding H
    Microb Pathog; 2020 Oct; 147():104255. PubMed ID: 32407861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence and Mechanism of Resistance of Tulathromycin Against
    Xia X; Yang L; Ling Y; Yu J; Ding H
    Front Vet Sci; 2022; 9():801800. PubMed ID: 35224081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against
    Zhang H; Mao C; Li J; Huang Z; Gu X; Shen X; Ding H
    Front Pharmacol; 2019; 10():1088. PubMed ID: 31620004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.
    Zhang N; Gu X; Ye X; Wu X; Zhang B; Zhang L; Shen X; Jiang H; Ding H
    Front Microbiol; 2016; 7():653. PubMed ID: 27199972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dose regimen formulation of tilmicosin against Lawsonia intracellularis in pigs by pharmacokinetic-pharmacodynamic (PK-PD) model.
    Luo W; Qin H; Chen D; Wu M; Meng K; Zhang A; Pan Y; Qu W; Xie S
    Microb Pathog; 2020 Oct; 147():104389. PubMed ID: 32707311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic susceptibility testing of Mycoplasma hyopneumoniae field isolates from Central Europe for fifteen antibiotics by microbroth dilution method.
    Felde O; Kreizinger Z; Sulyok KM; Hrivnák V; Kiss K; Jerzsele Á; Biksi I; Gyuranecz M
    PLoS One; 2018; 13(12):e0209030. PubMed ID: 30533041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility monitoring of Mycoplasma hyopneumoniae isolated from seven European countries during 2015-2016.
    de Jong A; Youala M; Klein U; El Garch F; Moyaert H; Simjee S; Maes D; Gyuranecz M; Pridmore A; Thomson JR; Ayling RD;
    Vet Microbiol; 2021 Feb; 253():108973. PubMed ID: 33418394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro pharmacodynamics of gamithromycin against Mycoplasma mycoides subspecies mycoides Small Colony.
    Mitchell JD; Goh S; McKellar QA; McKeever DJ
    Vet J; 2013 Sep; 197(3):806-11. PubMed ID: 23810743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.
    Huang Z; Mao C; Wei Y; Gu X; Cai Q; Shen X; Ding H
    PLoS One; 2020; 15(6):e0220350. PubMed ID: 32544163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/pharmacodynamic integration of tilmicosin against
    Chen Y; Ji X; Zhang S; Wang W; Zhang H; Ding H
    Front Vet Sci; 2023; 10():1260990. PubMed ID: 37732140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the ability of tilmicosin to prevent adherence of Mycoplasma hyopneumoniae to cilia using a differentiated swine respiratory epithelial culture system.
    Thacker EL; Young TF; Erickson BZ; DeBey MC
    Vet Ther; 2001; 2(4):293-300. PubMed ID: 19746651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae.
    Hannan PC; Windsor HM; Ripley PH
    Res Vet Sci; 1997; 63(2):157-60. PubMed ID: 9429250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PK-PD integration of enrofloxacin and cefquinome alone and in combination against
    Wei Y; Ji X; Zhang F; Zhang S; Deng Q; Ding H
    Front Pharmacol; 2023; 14():1226936. PubMed ID: 37869750
    [No Abstract]   [Full Text] [Related]  

  • 16. The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.
    Zhang P; Hao H; Li J; Ahmad I; Cheng G; Chen D; Tao Y; Huang L; Wang Y; Dai M; Liu Z; Yuan Z
    Front Microbiol; 2016; 7():385. PubMed ID: 27047487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The minimum inhibitory concentration of tilmicosin and tylosin for mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks.
    Jordan FT; Horrocks BK
    Avian Dis; 1996; 40(2):326-34. PubMed ID: 8790882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic integration of amphenmulin: a novel pleuromutilin derivative against
    Wang W; Yu J; Ji X; Xia X; Ding H
    Microbiol Spectr; 2024 Feb; 12(2):e0367523. PubMed ID: 38112481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Minimum Inhibitory Concentrations for 154 Mycoplasma synoviae isolates from Italy collected during 2012-2017.
    Catania S; Bottinelli M; Fincato A; Gastaldelli M; Barberio A; Gobbo F; Vicenzoni G
    PLoS One; 2019; 14(11):e0224903. PubMed ID: 31697761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PK-PD Relationship and Resistance Development of Danofloxacin against
    Zhang N; Wu Y; Huang Z; Yao L; Zhang L; Cai Q; Shen X; Jiang H; Ding H
    Front Microbiol; 2017; 8():926. PubMed ID: 28611739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.